NERLYNX + capecitabine protects against progression3
PFS IN PATIENTS WITH HER2+ mBC VS LAPATINIB
- NERLYNX + capecitabine significantly improved median PFS vs lapatinib + capecitabine: 5.6 months with NERLYNX + capecitabine vs 5.5 months with lapatinib + capecitabine (HR=0.76; 95% CI: 0.63, 0.93; P=0.0059)3
- Median overall survival trended in favor of NERLYNX + capecitabine in patients with HER2+ mBC: 21 months with NERLYNX + capecitabine vs 18.7 months with lapatinib + capecitabine (HR=0.88; 95% CI: 0.72, 1.07; P=0.2086)3
CI: confidence interval; HER: human epidermal growth factor receptor; HR: hazard ratio; mBC: metastatic breast cancer; PFS: progression-free survival.
Select IMPORTANT SAFETY INFORMATION
Embryo-Fetal Toxicity: NERLYNX can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception.
Lactation: Advise women not to breastfeed.
Please see additional IMPORTANT SAFETY INFORMATION below.